辉瑞公司同意在立普妥反垄断诉讼中以 9300 万美元和解，该诉讼涉嫌与兰伯西勾结阻止仿制药销售。 Pfizer agrees to $93m settlement in Lipitor antitrust lawsuit over alleged collusion with Ranbaxy to block generic sales.
辉瑞公司同意支付 9300 万美元，以和解与其胆固醇药物立普妥相关的反垄断诉讼。 Pfizer has agreed to pay $93 million to settle an antitrust lawsuit related to its cholesterol drug Lipitor. 该案件由药品批发分销商提起，指控辉瑞与印度兰伯西实验室勾结，推迟销售更便宜的仿制立普妥。 The case was filed by wholesale drug distributors and accused Pfizer of colluding with India’s Ranbaxy Laboratories to delay the sale of cheaper, generic versions of Lipitor. 经过十多年的法律斗争后，该和解协议尚待法官批准。 The settlement, which is subject to a judge's approval, comes after more than a decade of legal battles. 辉瑞公司称这些指控“在事实和法律上都毫无根据”。 Pfizer has called the allegations “factually and legally without merit.”